| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $39,921,231 | 11 | 100 |
| Elazzouzi Amy | Senior Vice President, Finance | 0 | $0 | 2 | $50,942 | $-50,942 |
| Plavsic Mark | Chief Technology Officer | 0 | $0 | 1 | $80,245 | $-80,245 |
| Gibney Anthony S | See Remarks | 0 | $0 | 1 | $82,330 | $-82,330 |
| Kilroy Conor | See Remarks | 0 | $0 | 2 | $143,400 | $-143,400 |
| Hopkins Janet Jill | Chief Medical Officer | 0 | $0 | 2 | $195,960 | $-195,960 |
| de los Pinos Elisabet | See Remarks | 0 | $0 | 2 | $323,369 | $-323,369 |
| Matrix Capital Management Company, LP | 10 percent owner | 0 | $0 | 1 | $39.04M | $-39.04M |
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential …
Over the last 12 months, insiders at Aura Biosciences, Inc. have bought $0 and sold $39.92M worth of Aura Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Aura Biosciences, Inc. have bought $7.69M and sold $8.38M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $98,000 was made by Johnson David Michael (director) on 2025‑05‑16.
| 2026-06-16 | Sale | Gibney Anthony S | See Remarks | 12,824 0.0199% | $6.42 | $82,330 | +11.46% | |
| 2026-05-07 | Sale | Matrix Capital Management Company, LP | 10 percent owner | 6.92M 7.4168% | $5.64 | $39.04M | -14.63% | |
| 2026-04-16 | Sale | Kilroy Conor | See Remarks | 11,738 0.0181% | $7.02 | $82,401 | -0.71% | |
| 2026-02-17 | Sale | de los Pinos Elisabet | See Remarks | 47,648 0.0723% | $5.06 | $241,099 | +31.14% | |
| 2026-02-17 | Sale | Hopkins Janet Jill | Chief Medical Officer | 20,401 0.031% | $5.06 | $103,229 | +31.14% | |
| 2026-02-17 | Sale | Plavsic Mark | Chief Technology Officer | 15,890 0.0241% | $5.05 | $80,245 | +31.14% | |
| 2026-02-17 | Sale | Kilroy Conor | See Remarks | 12,079 0.0183% | $5.05 | $60,999 | +31.14% | |
| 2026-02-17 | Sale | Elazzouzi Amy | Senior Vice President, Finance | 8,549 0.013% | $5.06 | $43,258 | +31.14% | |
| 2026-01-20 | Sale | de los Pinos Elisabet | See Remarks | 16,928 0.0261% | $4.86 | $82,270 | +36.22% | |
| 2026-01-20 | Sale | Elazzouzi Amy | Senior Vice President, Finance | 1,581 0.0024% | $4.86 | $7,684 | +36.22% | |
| 2025-11-17 | Sale | Hopkins Janet Jill | Chief Medical Officer | 17,109 0.0266% | $5.42 | $92,731 | +18.36% | |
| 2025-10-29 | Sale | de los Pinos Elisabet | See Remarks | 9,049 0.0163% | $6.35 | $57,461 | +5.21% | |
| 2025-10-29 | Sale | Elazzouzi Amy | Senior Vice President, Finance | 896 0.0016% | $6.35 | $5,690 | +5.21% | |
| 2025-10-16 | Sale | Plavsic Mark | Chief Technology Officer | 12,169 0.0201% | $6.35 | $77,273 | +4.20% | |
| 2025-08-18 | Sale | Elazzouzi Amy | Senior Vice President, Finance | 7,722 0.0124% | $6.70 | $51,737 | -5.23% | |
| 2025-05-16 | Sale | Gibney Anthony S | See Remarks | 1,519 0.0026% | $5.15 | $7,823 | +4.12% | |
| 2025-05-16 | Johnson David Michael | director | 20,000 0.0328% | $4.90 | $98,000 | +4.12% | ||
| 2025-05-16 | Gibney Anthony S | See Remarks | 50,000 0.0819% | $4.90 | $245,000 | +4.12% | ||
| 2025-04-16 | Sale | Kilroy Conor | See Remarks | 7,162 0.0142% | $5.49 | $39,319 | +13.43% | |
| 2025-04-16 | Sale | Elazzouzi Amy | Senior Vice President, Finance | 897 0.0018% | $5.49 | $4,925 | +13.43% |
| Gibney Anthony S | See Remarks | 265354 0.2559% | $1.66M | 1 | 2 | +4.12% |
| Matrix Capital Management Company, LP | 10 percent owner | 0 0% | $0 | 3 | 1 | <0.0001% |
| Medicxi Ventures Management (Jersey) Ltd | director | 2969352 2.8633% | $18.53M | 1 | 0 | <0.0001% |
| Johnson David Michael | director | 166167 0.1602% | $1.04M | 10 | 0 | <0.0001% |
$10,154,205 | 103 | -4.60% | $631.34M | |
$860,541,348 | 82 | -5.10% | $649.64M | |
$1,344,238 | 38 | 23.07% | $639.18M | |
$59,156,363 | 22 | 29.25% | $686.5M | |
$22,365,077 | 19 | -27.47% | $674.89M |
| Increased Positions | 53 | +44.17% | 1M | +2.83% |
| Decreased Positions | 47 | -39.17% | 3M | -5.58% |
| New Positions | 20 | New | 288,939 | New |
| Sold Out Positions | 9 | Sold Out | 894,920 | Sold Out |
| Total Postitions | 126 | +5% | 50M | -2.75% |
| Matrix Capital Management Company, Lp | $36,691.00 | 10.82% | 6.92M | 0 | 0% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $27,030.00 | 7.97% | 5.1M | 0 | 0% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $25,870.00 | 7.63% | 4.88M | 0 | 0% | 2025-09-30 |
| Long Focus Capital Management, Llc | $24,484.00 | 7.22% | 4.62M | 0 | 0% | 2025-09-30 |
| Suvretta Capital Management, Llc | $23,176.00 | 6.83% | 4.37M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $18,049.00 | 5.32% | 3.41M | +302,953 | +9.77% | 2025-09-30 |
| Medicxi Ventures Management (Jersey) Ltd | $16,111.00 | 4.75% | 3.04M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $15,320.00 | 4.52% | 2.89M | +413,001 | +16.67% | 2025-09-30 |
| Franklin Resources Inc | $11,654.00 | 3.44% | 2.2M | -141,895 | -6.06% | 2025-09-30 |
| Nantahala Capital Management, Llc | $11,224.00 | 3.31% | 2.12M | 0 | 0% | 2025-09-30 |